Simplified diagnosis of rare eye diseases – Uveitis experts provide an overview of an underestimated imaging technique

Uveitis is a rare inflammatory eye disease. Posterior and panuveitis in particular are associated with a poor prognosis and a protracted course of the disease. Diagnosis and monitoring can be challenging for healthcare professionals. Fundus autofluorescence (FAF) is a fast and non-invasive imaging technique that supports this. Researchers from the University Hospital Bonn and the University of Bonn, together with experts from Berlin, Münster and Mannheim, have drafted a review on how FAF can facilitate the diagnosis and monitoring of posterior uveitis and panuveitis. The results have now been published in the journal „Biomolecules“.

Background Research:

Uveitis is a rare eye disease and an inflammatory condition that causes swelling and destroys eye tissues. This inflammations can occur in different parts of the eye and can lead to reduced vision or blindness if not treated promptly.

Types of Uveitis are categorised based on which part of the eye is affected: anterior uveitis (affecting the front of the eye), intermediate uveitis (affecting the middle section, posterior uveitis (affecting the back part) and panuveitis (when all parts are affected).

Researchers from University Hospital Bonn, Berlin, Münster and Mannheim have reviewed Fundus autofluorescence (FAF). FAF is a diagnostic procedure that uses fluorescent light to illuminate areas of degeneration in an otherwise healthy retina. This allows doctors to visualize more details about retinal health than standard ophthalmic examination techniques.

On their review published in „Biomolecules“, they state how FAF simplifies diagnosis & monitoring process for Posterior Uveitis and Panuveitis, both having poor prognosis due to their relentless nature.

FAQ:
1. What is Uveitis?
– Uveitis is an inflammation of one or more parts within the uveal tract in your eyes. It’s a rare yet serious condition as it can lead to blindness if left untreated.

2. What are ‚posterior‘ uveiits & ‚panuveitiis‘?
– Posterior Uveiits affects back part area while Pan-Uviets affects all parts inside patient’s eyes.Their impact tends pull out adverse effect on eyesight with complex diagnosis & treatment process

3.What exactly does this new investigation bring forward?
– The research brought forth significance use Fundus Autoliuorescen(likened as FAF), non-invasive imaging technique.Its efficient method significantly helps healthcare professionals combat diagnostic challenges for Posterior/Pan-Uvetis

4. What is FAF?
– Fundus autofliorescence (FAF) an eye imaging technique uses fluorescent light to illuminate areas of retinal degeneration / damage in a healthier retina. It visualizes more details about retinal health conditions compared to standard examination techniques.

5. Why FAF is such an essential tool according to the research?
– Researchers believe FAF provides fast, non-invasive method which simplifies challenging Uveits diagnosis/monitoring process.Actually its use can improve prognosis, progression & overall course for serious variants like Posterior&Pauveitue.

6.Where was this reasearch published
– This research has been published in scientific journal known as „Biomolecules“.

7.Who were involved in the research?
– The study was carried by various researchers from University Hospital Bonn, universities of Berlin, Münster and Mannheim.

Originamitteilung:

Uveitis is a rare inflammatory eye disease. Posterior and panuveitis in particular are associated with a poor prognosis and a protracted course of the disease. Diagnosis and monitoring can be challenging for healthcare professionals. Fundus autofluorescence (FAF) is a fast and non-invasive imaging technique that supports this. Researchers from the University Hospital Bonn and the University of Bonn, together with experts from Berlin, Münster and Mannheim, have drafted a review on how FAF can facilitate the diagnosis and monitoring of posterior uveitis and panuveitis. The results have now been published in the journal „Biomolecules“.

share this recipe:
Facebook
Twitter
Pinterest

Weitere spannende Artikel

ERC Consolidator Grant für Georg Winter gibt rasant wachsendem Forschungsfeld weiteren Auftrieb

Maßgeschneiderte kleine Moleküle, die sich an Krebs verursachende Proteine heften und Tumorzellen dadurch unschädlich machen – das ist Georg Winters Spezialgebiet, in dem sich der Forschungsgruppenleiter am CeMM der ÖAW als weltweit führender Experten etabliert hat. Sein neuestes ERC CoG Projekt GENEomorph hebt seine Forschung auf eine neue Ebene: Anstatt Krebsproteine wie bisher für die zelluläre Müllabfuhr zu markieren, nimmt Winter mit seinen Design-Molekülen nun sogenannte Transkriptionsfaktoren ins Visier, ein vielversprechender Weg für neue Medikamente. Das sieht auch der Europäische Forschungsrat ERC so: Er fördert dieses Projekt in den nächsten fünf Jahren mit 1,9 Millionen Euro.

Read More